Open AccessExperience of effective antiviral therapy in a liver recipient with recurrent HCV infection genotype 1
Author(s) -
Д. В. Умрик,
О. М. Цирульникова,
И. А. Милосердов,
Р. А. Латыпов,
Е. Т. Егорова
Publication year - 2019
Publication title -
vestnik transplantologii i iskusstvennyh organov
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.137
H-Index - 5
eISSN - 2412-6160
pISSN - 1995-1191
DOI - 10.15825/1995-1191-2018-4-54-60
Subject(s) - hepatocellular carcinoma , cirrhosis , genotype , liver transplantation , medicine , antiviral therapy , transplantation , adverse effect , hepatitis c virus , hepatitis c , immunology , gastroenterology , virus , biology , chronic hepatitis , gene , biochemistry
HCV infection is one of the most common causes leading to the development of terminal liver diseases – cirrhosis and hepatocellular carcinoma, the main treatment for which is orthotopic liver transplantation. However, with continued virus replication, 100% reinfection occurs, which leads to the rapid progression of cirrhosis of the graft and the loss of its function. Standard interferon-containing therapy is ineffective for HCV infection, especially genotype 1, both before and after transplantation, and also has a wide range of adverse events. The article presents the successful experience of treating the recurrence of HCV infection 1 genotype in a patient who underwent liver transplantation and several courses of ineffective antiviral therapy.